BioSpace News Archive

Dalrada Corporation (OTCQB: DFCO, “Dalrada”) is excited to share information on the Company’s community outreach efforts that support free, on-site COVID-19 point-of-care tests at in-person events.

Gritstone bio, Inc., a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies and vaccines, announced a $55.0 million private investment in public equity financing from the sale of 5,000,000 shares of its common stock at a price per share of $11.00.

SeaSpine Holdings Corporation announced today that it will host an Analyst & Investor Event in Boston, Massachusetts on Thursday, September 30 from 7:30 a.m. to 8:45 a.m. Eastern Time.

The U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis (PEP) in certain individuals for the prevention of SARS-CoV-2 infection, Eli Lilly and Company (NYSE: LLY) announced today.

ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will participate in the Cantor Global Healthcare Conference.

Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunology therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, today announced the presentation of new preclinical data from the Company’s investigational therapy, ACT-903 at the European Society of Medical Oncology (ESMO) Annual Meeting

Tarveda Therapeutics, Inc. (“Tarveda”), a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, today announced that the company has entered into a collaboration and license agreement with SciClone Pharmaceuticals (Holdings) Limited (“SciClone”).

Evofem Biosciences, Inc., today announced that seven data sets from clinical trials of Phexxi® (lactic acid, citric acid and potassium bitartrate) and EVO100 will be presented at four medical society meetings in October 2021 .

Cardialen , Inc., has been awarded a $3 million National Institutes of Health (NIH) Phase IIb SBIR grant for the development of an implantable, low-energy therapy for the cardioversion of atrial fibrillation (AF).

Radialis Medical today announced that it has submitted a U.S. Food & Drug Administration (FDA) 510(k) premarket notification for the Radialis PET Camera, an organ-targeted positron emission tomography (PET) system.